OXUR.BR

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$30M	+2928.0%	$-12000.00	$-12000.00–$-12000.00	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 2 reported quarters

Reported	Est. EPS	Actual	Surprise
2023-03-24	$-3600.00	$-526.80	+85.4%
2022-09-07	$-3900.00	$-3200.00	+17.9%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
OXUR.BROxurion N.V.	$0.00	+0.00%	$365910	—
ARGX.BRargenx SE	$861.80	-0.69%	$53.6B	—
BIOS.BRBioSenic S.A.	$0.00	+0.00%	$1M	—
CYAD.BRCelyad Oncology S.A.	$0.26	+14.16%	$12M	—
HYL.BRHyloris Pharmaceuticals S.A.	$4.20	+0.00%	$118M	—
ONWD.BROnward Medical N.V.	$2.73	-0.18%	$127M

Source: Financial Modeling Prep · peers by sector/industry

Oxurion N.V.

Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.

www.oxurion.com

Employees: 26
IPO / List date: Jul 7, 2006
HQ: BE

Held by traders on TradeandTell

No one on the platform currently holds OXUR.BR.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in OXUR.BR as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded OXUR.BR yet.